# A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

> **NCT07310420** · PHASE1 · RECRUITING · sponsor: **TerSera Therapeutics LLC** · enrollment: 88 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** ZOLADEX

## Key facts

- **NCT ID:** NCT07310420
- **Lead sponsor:** TerSera Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-29
- **Primary completion:** 2026-11-30
- **Final completion:** 2027-03-30
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07310420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07310420, "A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT07310420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*